Qualigen Therapeutics Inc. (NASDAQ: QLGN)
$0.33
-0.0546 ( -14.10% ) 4.2M
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
Market Data
Open
$0.33
Previous close
$0.39
Volume
4.2M
Market cap
$3.20M
Day range
$0.33 - $0.38
52 week range
$0.14 - $1.26
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | Mar 28, 2024 |
8-k | 8K-related | 18 | Feb 27, 2024 |
8-k | 8K-related | 15 | Feb 22, 2024 |
8-k | 8K-related | 13 | Dec 07, 2023 |
8-k | 8K-related | 13 | Nov 22, 2023 |
10-q | Quarterly Reports | 69 | Nov 14, 2023 |
8-k | 8K-related | 13 | Nov 14, 2023 |
8-k | 8K-related | 14 | Nov 08, 2023 |
8-k | 8K-related | 34 | Oct 17, 2023 |
8-k | 8K-related | 13 | Sep 28, 2023 |